tiprankstipranks
Eliem Therapeutics (ELYM)
NASDAQ:ELYM
US Market
Holding ELYM?
Track your performance easily

Eliem Therapeutics (ELYM) Income Statement

47 Followers

Eliem Therapeutics Income Statement

Last quarter (Q2 2024), Eliem Therapeutics's total revenue was $33.00K, an increase of Infinity% from the same quarter last year. In Q2, Eliem Therapeutics's net income was $-54.89M. See Eliem Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 33.00K---$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
$ 33.00K-----
Operating Expense
$ 71.09M$ 40.27M$ 45.13M$ -35.67M$ 20.93M$ 7.45M
Operating Income
$ -71.09M$ -40.27M$ -45.13M$ -35.59M$ -20.93M$ -7.45M
Net Non Operating Interest Income Expense
------
Other Income Expense
$ -2.61M$ -356.00K$ 235.00K$ 11.84M$ 257.00K$ 899.00K
Pretax Income
$ -14.03M$ -39.92M$ -45.48M$ -47.60M$ -20.67M$ -6.55M
Tax Provision
---$ -219.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -65.77M$ -35.12M$ -45.24M$ -52.15M$ -22.95M$ -7.39M
Basic EPS
$ -2.21$ -1.30$ -1.72$ -4.24$ -3.36$ -1.08
Diluted EPS
$ -2.21$ -1.30$ -1.72$ -4.24$ -3.36$ -1.08
Basic Average Shares
$ 111.90M$ 26.99M$ 26.31M$ 12.26M$ 6.84M$ 6.84M
Diluted Average Shares
$ 111.90M$ 26.99M$ 26.31M$ 12.26M$ 6.84M$ 6.84M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 71.09M$ 40.27M$ 45.13M$ -35.67M$ 20.93M$ 7.45M
Net Income From Continuing And Discontinued Operation
$ -65.77M$ -35.12M$ -45.24M$ -47.60M$ -20.67M$ -6.55M
Normalized Income
$ -10.97M---$ -20.93M$ -6.53M
Interest Expense
------
EBIT
$ -68.06M$ -35.12M$ -45.48M$ -47.60M$ -20.93M$ -7.45M
EBITDA
$ -68.80M$ -35.12M$ -45.66M$ -47.23M$ -20.93M$ -7.45M
Currency in USD

Eliem Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis